May 14, 2018

Zevalin Plus Aggressive Chemotherapy Safe, Effective for Follicular Lymphoma, Phase 2 Trial Shows

News

Supplementing an aggressive chemotherapy regimen with Zevalin (ibritumomab tiuxetan) is safe and provides improved clinical response in patients with intermediate or high-risk follicular lymphoma, results from a Phase 2 clinical trial show. ... Read more

February 2, 2018February 2, 2018

Aggressive Treatment Seen to Help Advanced Follicular Lymphoma Patients in Phase 2 Trial

News

Sequential chemoimmunotherapy, radioimmunotherapy, and maintenance treatment with Rituxan (rituximab) improves progression-free survival and delays disease progression in patients with untreated advanced follicular lymphoma, Phase 2 clinical trial data shows. The study reporting ... Read more